Immuneering Co. (NASDAQ:IMRX) Expected to Post Quarterly Sales of $220,000.00

Equities analysts expect that Immuneering Co. (NASDAQ:IMRX – Get Rating) will report sales of $220,000.00 for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Immuneering’s earnings. The lowest sales estimate is $190,000.00 and the highest is $300,000.00. The company is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Immuneering will report full-year sales of $740,000.00 for the current year, with estimates ranging from $570,000.00 to $1.00 million. For the next year, analysts anticipate that the business will report sales of $800,000.00. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Immuneering.

Immuneering (NASDAQ:IMRX – Get Rating) last posted its quarterly earnings data on Thursday, March 10th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.03). The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.60 million.

Several analysts recently issued reports on IMRX shares. Guggenheim decreased their price objective on shares of Immuneering from $42.00 to $30.00 in a report on Monday, January 3rd. Zacks Investment Research cut shares of Immuneering from a “buy” rating to a “hold” rating in a research note on Monday, March 14th. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 target price on shares of Immuneering in a research note on Thursday, December 30th. Oppenheimer assumed coverage on shares of Immuneering in a research note on Thursday, March 31st. They set an “outperform” rating and a $25.00 target price for the company. Finally, Piper Sandler initiated coverage on shares of Immuneering in a research note on Friday, January 7th. They set an “overweight” rating and a $41.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $30.17.

In other Immuneering news, Director Ann E. Berman acquired 6,000 shares of the company’s stock in a transaction dated Tuesday, March 15th. The stock was bought at an average price of $6.40 per share, for a total transaction of $38,400.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders bought 9,900 shares of company stock valued at $69,201.

Several institutional investors have recently made changes to their positions in IMRX. UBS Group AG acquired a new stake in shares of Immuneering during the 3rd quarter worth about $30,000. Citigroup Inc. acquired a new stake in shares of Immuneering during the 3rd quarter worth about $33,000. New York State Common Retirement Fund acquired a new stake in shares of Immuneering during the 3rd quarter worth about $45,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Immuneering during the 3rd quarter worth about $75,000. Finally, JPMorgan Chase & Co. increased its position in shares of Immuneering by 72.2% during the 4th quarter. JPMorgan Chase & Co. now owns 5,454 shares of the company’s stock worth $88,000 after purchasing an additional 2,287 shares in the last quarter. Institutional investors and hedge funds own 46.75% of the company’s stock.

NASDAQ IMRX opened at $6.07 on Friday. The company has a fifty day simple moving average of $7.22 and a 200 day simple moving average of $15.77. Immuneering has a 1 year low of $5.89 and a 1 year high of $33.99.

About Immuneering (Get Rating)

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.

Read More